Boehringer Ingelheim to Acquires Labor Dr. Merk & Kollegen for Boosting its Next Generation Cancer Immunology Program

Shots:

  • The acquisition will enable Boehringer Ingelheim to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the VSV with modified GP platform and cancer vaccines platforms
  • The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development capabilities
  • Boehringer Ingelheim focuses to accelerate the delivery of first-in-class immuno-oncology therapies to patients across the globe

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Labor Merk

The post Boehringer Ingelheim to Acquires Labor Dr. Merk & Kollegen for Boosting its Next Generation Cancer Immunology Program first appeared on PharmaShots.